Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

被引：2

作者：

Spraggs, C. F. ^{[1
]}

Parham, L. R. ^{[2
]}

Song, K. ^{[3
]}

Briley, L. P. ^{[2
]}

Johnson, T. ^{[1
]}

Russo, M. ^{[3
]}

Tada, H. ^{[3
]}

du Bois, A. ^{[4
]}

Xu, C. -F. ^{[1
]}

机构：

[1] GlaxoSmithKline Res & Dev Ltd, Stevenage, Herts, England

[2] PAREXEL Int, Durham, England

[3] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA

[4] Kliniken Essen Mitte, Essen, Germany

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷 / 07期

关键词：

CHRONIC MYELOID-LEUKEMIA; CHINESE INDIVIDUALS; CANNOT ACCOUNT; RESISTANCE;

D O I：

10.1093/annonc/mdv211

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Previous reports suggest that an inherited BIM deletion polymorphism is associated with clinical resistance to EGFR-targeted TKI therapy in EGFR-mutated NSCLC. Herein we evaluate the potential association of BIM deletion with response to TKI treatment in renal cell carcinoma, ovarian cancer, and HER2-overexpressing metastatic breast cancer.

引用

页码：1515 / 1517

页数：3

共 22 条

[21] Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors' Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
Zhang, Lijuan
Tian, Meng
Lin, Jiamao
Zhang, Jianbo
Wang, Haiyong
Li, Zhenxiang
FRONTIERS IN ONCOLOGY, 2021, 10
[22] Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR
Haspinger, Eva Regina
Agustoni, Francesco
Torri, Valter
Gelsomino, Francesco
Platania, Marco
Zilembo, Nicoletta
Gallucci, Rosaria
Garassino, Marina Chiara
Cinquini, Michela
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (02) : 213 - 227

← 1 2 3 →